The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease.

ABSTRACT: Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). Liver injury from oxaliplatin ranges from mild liver enzyme increases in 42% to 57% of patients in clinical trials¹ to rare severe injury leading to acute liver failure.² Chronic injury from endothelial cell damage and architectural distortion may manifest years later with nodular regenerative hyperplasia (NRH), portal sclerosis, and noncirrhotic portal hypertension (NCPH).^2,3 Chronic subclinical injury occurs in up to 78% of patients.³ Diagnosis may be confounded by nonalcoholic fatty liver disease (NAFLD), and long-term outcomes from chronic injury are unclear.

SUBMITTER: Kim HP 

PROVIDER: S-EPMC8007645 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature